How do you treat an uncomplicated urinary tract infection in a non‑pregnant adult with normal renal function and no drug allergies?

Treatment of Uncomplicated Urinary Tract Infection in Adults

For an otherwise healthy, non-pregnant adult with normal renal function and no drug allergies presenting with uncomplicated UTI, prescribe nitrofurantoin 100 mg orally twice daily for 5 days as first-line therapy. This regimen achieves approximately 93% clinical cure and 88% microbiological eradication while maintaining worldwide resistance rates below 1%, and it causes minimal disruption to intestinal flora compared with fluoroquinolones or broad-spectrum agents. 1

First-Line Treatment Options

Nitrofurantoin (Preferred)

• Nitrofurantoin 100 mg orally twice daily for 5 days provides superior efficacy to beta-lactams and better preservation of intestinal microbiota, reducing the risk of Clostridioides difficile infection. 1
• This agent retains excellent activity against E. coli (responsible for 75–95% of uncomplicated cystitis cases) despite minimal resistance. 1
• Contraindication: Do not use when estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m², as adequate urinary concentrations cannot be achieved. 1

Trimethoprim-Sulfamethoxazole (TMP-SMX)

• TMP-SMX 160/800 mg orally twice daily for 3 days achieves 93% clinical cure and 94% microbiological eradication when the causative organism is susceptible. 1
• Use only when local E. coli resistance is <20% and the patient has not received TMP-SMX in the preceding 3 months. 2, 1
• Many regions now report TMP-SMX resistance >20%, necessitating verification of local antibiogram data before empirical selection. 1

Fosfomycin

• Fosfomycin trometamol 3 g as a single oral dose provides approximately 91% clinical cure, maintains therapeutic urinary concentrations for 24–48 hours, and shows initial-infection resistance rates around 2.6%. 1
• The single-dose regimen improves adherence compared with 3–7 day courses. 1
• Do not use for suspected pyelonephritis or upper-tract infections due to insufficient tissue penetration. 2, 1

Reserve (Second-Line) Agents

Fluoroquinolones

• Ciprofloxacin 250–500 mg orally twice daily for 3 days or levofloxacin 250–750 mg orally once daily for 3 days should be reserved exclusively for culture-proven resistant pathogens or documented failure of first-line agents. 1, 3
• The FDA advisory (July 2016) recommends against fluoroquinolone use for uncomplicated UTIs because serious adverse effects (tendon rupture, peripheral neuropathy, CNS toxicity) outweigh benefits. 1
• Global fluoroquinolone resistance is rising, with some regions reporting >10% resistance among uropathogens. 1

Beta-Lactams

• Amoxicillin-clavulanate, cefdinir, or cefpodoxime for 3–7 days achieve only 89% clinical cure and 82% microbiological eradication, which is significantly inferior to first-line agents. 1
• Amoxicillin or ampicillin alone should never be used because worldwide E. coli resistance exceeds 55–67%. 1

Diagnostic Approach

When Urine Culture Is NOT Required

• Routine urine culture is not required for otherwise healthy women presenting with typical lower-tract symptoms (dysuria, frequency, urgency) in the absence of vaginal discharge. 1

When Urine Culture IS Mandatory

• Obtain culture and susceptibility testing when any of the following occur:
  • Persistent symptoms after completing the prescribed regimen 1
  • Recurrence of symptoms within 2–4 weeks 1
  • Fever >38°C, flank pain, or costovertebral angle tenderness suggesting pyelonephritis 2, 1
  • Atypical presentation or presence of vaginal discharge 1
  • History of recurrent infections or prior isolation of resistant organisms 1

Management of Treatment Failure

• If symptoms do not resolve by the end of therapy or recur within 2 weeks, obtain a urine culture and susceptibility test immediately and switch to a different antibiotic class for a 7-day course (not the original short regimen). 1
• Reserve fluoroquinolones only for culture-proven resistance. 1
• If fever persists beyond 72 hours, perform imaging (ultrasound or CT) to exclude obstruction or abscess. 2

Critical Pitfalls to Avoid

• Do not treat asymptomatic bacteriuria in non-pregnant, non-catheterized women, as this promotes resistance without clinical benefit. 1, 4
• Do not use empiric fluoroquinolones as first-line therapy for uncomplicated cystitis due to serious adverse effects and rising resistance. 1
• Do not prescribe TMP-SMX without confirming that local resistance is <20%; failure rates increase sharply above this threshold. 2, 1
• Do not use nitrofurantoin when eGFR <30 mL/min/1.73 m² or for suspected pyelonephritis. 1
• Do not use oral fosfomycin for suspected upper-tract infection or pyelonephritis. 2, 1

Treatment Algorithm

1. Confirm uncomplicated UTI (no fever, flank pain, pregnancy, catheter, immunosuppression, or recent instrumentation). 1
2. Assess local E. coli TMP-SMX resistance:
   • If <20% and no recent TMP-SMX use → prescribe TMP-SMX 160/800 mg twice daily for 3 days 2, 1
   • If ≥20% or local data unavailable → prescribe nitrofurantoin 100 mg twice daily for 5 days or fosfomycin 3 g single dose 1
3. If symptoms persist after 2–3 days or recur within 2 weeks:
   • Obtain urine culture and susceptibility testing 1
   • Switch to a different antibiotic class for a 7-day course 1
   • Reserve fluoroquinolones only for culture-proven resistance 1